Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.27 USD

74.27
1,261,827

+0.49 (0.66%)

Updated Aug 19, 2024 01:24 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx

Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.

    Horizon Pharma Completes Enrollment in Eye Disease Study

    Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.

      Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout

      Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.

        MannKind Stock Up on Licensing Deal With United Therapeutics

        MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.

          Alnylam's Shares Up as Onpattro Gets FDA and EU Approvals

          Shares of Alnylam (ALNY) increase due to the FDA and European approval for Onpattro.

            Novo Nordisk's Ozempic Lowers Risk of Cardiovascular Events (revised)

            Novo Nordisk (NVO) announces post hoc results from SUSTAIN 6 study demonstrating that Ozempic consistently reduces the risk of major cardiovascular (CV) events across type II diabetes population.

              Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine

              Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.

                AstraZeneca's Lupus Drug Misses Primary Endpoint in Study

                AstraZeneca's (AZN) phase III study, evaluating anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus, does not meet primary endpoint.

                  Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A

                  Bayer's (BAYRY) Jivi gets FDA approval for the treatment of hemophilia A in previously-treated adults and adolescents aged 12 years and older.

                    Alnylam Gets European Nod for First-Ever RNAi Therapeutic

                    Alnylam's (ALNY) Onpattro, the first ever RNA interference (RNAi) therapeutic, has been granted marketing authorization by the European Commission.

                      Merck (MRK) Receives FDA Approval for Two HIV Medicines

                      Merck's (MRK) two new HIV-1 medicines, Delstrigo and Pifeltro, get approval in the United States.

                        Bristol-Myers' Sprycel Seeks Label Expansion in the U.S.

                        The FDA accepts Bristol-Myers' (BMY) sBLA for label expansion of Sprycel for the treatment of pediatric patients with newly diagnosed Ph+ ALL.

                          Glaxo's Asthma Drug Gets EU Nod for Pediatric Population

                          Glaxo (GSK) gains EU approval for asthma drug Nucala as an add-on treatment for severe refractory eosinophilic asthma in children.

                            Vertex Inks Deal With Genomics to Make Serious Disease Drugs

                            Vertex (VRTX) signs a three-year collaboration contract with Genomics to develop novel drug targets for advancing discovery of precision medicines.

                              Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

                              Gilead Sciences (GILD) closed the most recent trading day at $76.29, moving +0.9% from the previous trading session.

                                Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

                                Gilead Sciences (GILD) closed the most recent trading day at $76.29, moving +0.9% from the previous trading session.

                                  Affimed (AFMD) Surges on Collaboration Contract with Roche (revised)

                                  Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

                                    Bausch (BHC) Resubmits NDA for Duobrii for Plaque Psoriasis

                                    Bausch Health Companies Inc. (BHC) resubmits its NDA for plaque psoriasis drug, Duobrii to the FDA and the agency has set a PDUFA action date of Feb 15, 2019.

                                      Ultragenyx to File NDA for LC-FAOD Candidate on Existing Data

                                      Ultragenyx (RARE) plans to submit an NDA for UX007 for the treatment of LC-FAOD on existing data, as per agreement with the FDA.

                                        Amgen's Leukemia Drug Blincyto Gets EU Nod for Pediatric Use

                                        Amgen's (AMGN) leukemia drug, Blincyto gets approval in EU for use in pediatric patients aged one year or older.

                                          Affimed (AFMD) Surges On Collaboration Contract With Roche

                                          Affimed (AFMD) inks a strategic collaboration deal with Roche to develop a host of immunotherapies for treating different types of cancer.

                                            Biotech Stock Roundup: GILD Gets EC Nod for Yescarta, AMGN Submits Kyprolis sNDA

                                            Regulatory and pipeline updates comprise some of the key developments in the biotech sector this week. These include Gilead's Yescarta approval in Europe.

                                              Ultragenyx's Rare Disease Drug Mepsevii Gets EU Approval

                                              Ultragenyx's (RARE) Mepsevii gets European approval for the treatment of Mucopolysaccharidosis VII.

                                                Bayer's Blood Thinner Xarelto Fails in Line Extension Studies

                                                Bayer (BAYRY) and partner Johnson & Johnson's drug, Xarelto shows no significant difference when compared with placebo in two late-stage phase III studies.

                                                  Amgen Files for Once-Weekly Regimen for Myeloma Drug Kyprolis

                                                  Amgen (AMGN) submits a supplemental new drug application to the FDA, seeking an approval for once-weekly dosage of its multiple myeloma drug, Kyprolis, combined with dexamethasone (Kd).